Mechanisms of Cancer Prevention: Effects of Protease Inhibitors on Proteases and Gene Expression
Our studies utilizing different Types of protease inhibitors as anticarcinogenic agents in in vivo and in vitro systems have recently been reviewed (1). These studies suggest that the protease inhibitors which prevent carcinogenesis are affecting processes in the early stages of carcinogenesis, although they can be effective at long time periods after carcinogen exposure in both in vitro and in vivo systems. While there is strong evidence that these protease inhibitors can affect both the initiation and promotion stages of carcinogenesis, they have no effect on cells which are already transformed. Our results have suggested that the first event in carcinogenesis is a high frequency epigenetic event and that a later event, presumably genetic, leads to the malignant state. Protease inhibitors appear to be capable of reversing the initiating event, presumably by stopping an ongoing cellular process begun by carcinogen exposure. The major lines of investigation on the mechanism of the protease inhibitor suppression of carcinogenesis relate to the ability of anticarcinogenic protease inhibitors to affect: 1) the expression of certain oncogenes, and 2) the levels of certain Types of proteolytic activities. The anticarcinogenic protease inhibitors have no observable effects on normal cells, but have the ability to reverse carcinogen-induced cellular changes for several different endpoints studied.
The most direct method of determining the mechanism of action of the anticarcinogenic protease inhibitors is to identify and characterize the proteases with which they interact. In the cells of the in vivo and in vitro systems in which we’ve observed that protease inhibitors can prevent carcinogenesis, only a few proteases have been observed to interact with the anticarcinogenic protease inhibitors. Proteases have been identified by both substrate hydrolysis and affinity chromatography. Utilizing substrate hydrolysis, we have examined the ability of cell homogenates to cleave specific substrates and have then determined the ability of various protease inhibitors to affect that hydrolyzing activity. Utilizing affinity chromatography, specific proteases directly interacting with the anticarcinogenic protease inhibitors can be identified. The Boc-Val-Pro-Arg-MCA hydrolyzing activity was identified by substrate hydrolysis and a 43 kDa protease has been identified by affinity chromatography. There is evidence that both of these different proteolytic activities are playing a role in the prevention of carcinogenesis by protease inhibitors.
Our studies on anticarcinogenic protease inhibitors have suggested that the Bowman-Birk Inhibitor (BBI), derived from soybeans, is a particularly effective anti-carcinogenic protease inhibitor. BBI has been studied both as a pure protease inhibitor, purified BBI (PBBI), and as an extract of soybeans enriched in BBI, termed BBI concentrate (BBIC). PBBI and/or BBIC have been shown to suppress carcinogenesis: 1) in three different species (mice, rats and hamsters), 2) in several organ systems/tissue Types (colon, liver, lung, esophagus and cheek pouch [oral epithelium]), 3) in cells of both epithelial and connective tissue origin, 4) when given to animals by several different routes of administration (including the diet), 5) leading to different Types of cancer (e.g., squamous cell carcinomas, adenocarcinomas, angiosarcomas, etc.), and 6) induced by a wide variety of chemical and physical carcinogens (1). We originally identified BBI as an anticarcinogenic agent in an in vitro transformation assay system. BBI, as BBIC, has recently risen to the human trial stage. In human trials, elevated levels of proteolytic activities known to be affected by BBI are serving as intermediate marker endpoints
human trials, elevated levels of proteolytic activities known to be affected by BBI are serving as intermediate marker endpoints (IME) in the cells of tissues at higher than normal risks of cancer development. In previous animal studies, we have observed that BBI is capable of bringing such elevated levels of proteolytic activity back to normal levels in normal appearing tissues. We have recently observed that BBI treatment can increase the levels of proteolytic activities in pre-malignant tissues. We hypothesize that the increased levels of proteolytic activities in pre-malignant cells and tissues are associated with a cell killing effect, leading to a degradation of the pre-malignant lesions. Although the mechanism for the anticarcinogenic effect(s) of BBI is unclear, BBI is a highly promising human cancer chemopreventive agent.
KeywordsHydrolysis Adenocarcinoma Superoxide Serine Trypsin
Unable to display preview. Download preview PDF.
- 4.Hwang, D.L.R., Davis-Lin, K.T., Yang, W.K. and Foard, D.T.: Purification, partial characterization and immunological relationships of multiple low molecular weight proteinase inhibitors of soybean. Biochem. Biophy. Acta. 495:369–382, 1977.Google Scholar
- 7.Yavelow, J., Finlay, T.H., Kennedy, A.R. and Troll, W.: Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res. 43: 2454–2459,1983.Google Scholar
- 10.Kennedy, A.R., Szuhaj, B.F., Newberne, P.M. and Billings, P.C.: Preparation and production of a cancer chemopreventive agent, Bowman-Birk Inhibitor Concentrate. Nutr. Cancer 19: 281–302,1993.Google Scholar
- 11.Kennedy, A.R.: Prevention of carcinogenesis by protease inhibitors. Cancer Res. (suppl.). 54: 1999s-2005s, 1994.Google Scholar
- 14.St. Clair, W., Billings, P., Carew, J., Keller-McGandy, C., Newberne, P. and Kennedy, A.R.: Suppression of DMHinduced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res. 50: 580–586, 1990.Google Scholar
- 16.Messadi, P.V., Billings, P., Shklar, G. and Kennedy, A.R.: Inhibition of oral carcinogenesis by a protease inhibitor. J. Natl. Cancer Inst. 76: 447–452,1986.Google Scholar
- 17.Kennedy, A.R., Billings, P.C., Maki, P.A. and Newberne, P.: Effects of various protease inhibitor preparations on oral carcinogenesis in hamsters induced by 7,12dimethylbenz(a)anthracene. Nutr. Cancer 19: 191–200,1993.Google Scholar
- 21.Chang, J.D., Billings, P. and Kennedy, A.R.: C-myc expression is reduced in antipain-treated proliferating C3H10T1002F2 cells. Biochem. Biophys. Res. Comm. 133: 830–835, 1985.Google Scholar
- 26.Li, J.-H., Billings, P.C. and Kennedy, A.R.: Induction of oncogene expression by sodium arsenite in C3H/ 10T1/2 cells; inhibition of c-myc expression by protease inhibitors. The Cancer Journal 5: 354–358,1992.Google Scholar
- 30.Billings, P.C., St. Clair, W. Owen, and Kennedy, A.R.: Potential intracellular target proteins of the anticarcinogenic Bowman-Birk protease inhibitor identified by affinity chromatography. Cancer Res. 48: 1798–1802,1988.Google Scholar
- 34.Billings, P.C., Habres, J.M., Liao, D.C. and Tuttle, S.W.: A protease activity in human fibroblasts which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Res. 51: 5539–5543,1991.Google Scholar
- 36.Billings, P.C.: Approaches to studying the target enzymes of anticarcinogenic protease inhibitors. In:Protease Inhibitors as Cancer Chemopreventive Agents, edited by Walter Troll and Ann R. Kennedy, Plenum Publishing Corporation, 1993.Google Scholar
- 39.Kennedy, A.R.: Promotion and other interactions between agents in the induction of transformation in vitro in fibroblasts. In: Mechanisms of Tumor Promotion, Vol. III, “Tumor Promotion and Carcinogenesis in vitro ” edited by T.J. Slaga, CRC Press, Inc., Chapter 2, pp. 13–55, 1984.Google Scholar
- 42.Yavelow, J., Caggana, M. and Beck, K.A.: Proteases occurring in the cell membrane: a possible receptor for the Bowman Birk Type of protease inhibitors. Cancer Res. 47:1598–1601, 1987.Google Scholar
- 44.Garte, S.J., Currie, D.C. and Troll, W.: Inhibition of H-ras oncogene transformation of NIH3T3 cells by protease inhibitors. Cancer Res. 47: 3159–3162,1987.Google Scholar
- 46.St. Clair, W.H. and St. Clair, D.K.: Effect of the Bowman-Birk protease inhibitor on the expression of oncogenes in the irradiated rat prostate. Cancer Res. 51: 4539–4543,1991.Google Scholar
- 47.Manzone, H., Billings, P.C., Cummings, W.N., Feldman, R., Odell, C.S., Horan, A., Atiba, J.O., Meyskens, F.L., Jr., and Kennedy, A.R.: Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. Cancer Epidemiology Biomarkers & Prevention (in press).Google Scholar
- 49.Garewal, H.S. and Meyskens, F., Jr.: Retinoids and carotenoids in the prevention of oral cancer: a critical appraisal. Cancer Epidem. Biomarkers Prevention 1: 155–159,1992.Google Scholar